Loading
After surgery or curative treatment, everyone gets regular blood tests for leftover cancer DNA, and the pooled results power forecasts of who will relapse and trials of acting early.
Circulating tumour DNA detects molecular residual disease months before imaging, and trials such as DYNAMIC and IMvigor011 show it can guide adjuvant decisions. Uptake is piecemeal and results are not pooled. The proposal is a national programme offering serial MRD testing to all patients treated with curative intent for high-risk cancers, with data flowing to a shared platform that continuously estimates relapse risk, feeds MRD-triggered trial randomisation, and reports test performance by tumour type and assay.
Shares ctDNA-triggered escalation in early TNBC, IMvigor011, DYNAMIC, Signatera.
Shares IMvigor011, DYNAMIC, Signatera, Dormant cells and minimal residual disease.
Shares Signatera, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing.
Shares IMvigor011, DYNAMIC, Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing.
Shares IMvigor011, Signatera, Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD).
Shares DYNAMIC, Signatera, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA).
Shares Signatera, Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA).
Shares Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing.